228 related articles for article (PubMed ID: 27815390)
1. Kv1.3 Channels Mark Functionally Competent CD8+ Tumor-Infiltrating Lymphocytes in Head and Neck Cancer.
Chimote AA; Hajdu P; Sfyris AM; Gleich BN; Wise-Draper T; Casper KA; Conforti L
Cancer Res; 2017 Jan; 77(1):53-61. PubMed ID: 27815390
[TBL] [Abstract][Full Text] [Related]
2. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
[TBL] [Abstract][Full Text] [Related]
3. Increased PD-1
Jie HB; Srivastava RM; Argiris A; Bauman JE; Kane LP; Ferris RL
Cancer Immunol Res; 2017 May; 5(5):408-416. PubMed ID: 28408386
[TBL] [Abstract][Full Text] [Related]
4. Analysis of tumor-infiltrating CD103 resident memory T-cell content in recurrent laryngeal squamous cell carcinoma.
Mann JE; Smith JD; Birkeland AC; Bellile E; Swiecicki P; Mierzwa M; Chinn SB; Shuman AG; Malloy KM; Casper KA; McLean SA; Moyer JS; Wolf GT; Bradford CR; Prince ME; Carey TE; McHugh JB; Spector ME; Brenner JC
Cancer Immunol Immunother; 2019 Feb; 68(2):213-220. PubMed ID: 30361882
[TBL] [Abstract][Full Text] [Related]
5. PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4
Mattox AK; Lee J; Westra WH; Pierce RH; Ghossein R; Faquin WC; Diefenbach TJ; Morris LG; Lin DT; Wirth LJ; Lefranc-Torres A; Ishida E; Chakravarty PD; Johnson L; Zeng YC; Chen H; Poznansky MC; Iyengar NM; Pai SI
Cancer Res; 2017 Nov; 77(22):6365-6374. PubMed ID: 28947422
[TBL] [Abstract][Full Text] [Related]
6. CD8+ and CD4+ tumour infiltrating lymphocytes in relation to human papillomavirus status and clinical outcome in tonsillar and base of tongue squamous cell carcinoma.
Nordfors C; Grün N; Tertipis N; Ährlund-Richter A; Haeggblom L; Sivars L; Du J; Nyberg T; Marklund L; Munck-Wikland E; Näsman A; Ramqvist T; Dalianis T
Eur J Cancer; 2013 Jul; 49(11):2522-30. PubMed ID: 23571147
[TBL] [Abstract][Full Text] [Related]
7. Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites.
Albers AE; Ferris RL; Kim GG; Chikamatsu K; DeLeo AB; Whiteside TL
Cancer Immunol Immunother; 2005 Nov; 54(11):1072-81. PubMed ID: 15959774
[TBL] [Abstract][Full Text] [Related]
8. Blockade of adenosine A2A receptor enhances CD8
Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: Immune cell subtypes, immuno-suppressive pathways and clinicopathologic characteristics.
Karpathiou G; Casteillo F; Giroult JB; Forest F; Fournel P; Monaya A; Froudarakis M; Dumollard JM; Prades JM; Peoc'h M
Oncotarget; 2017 Mar; 8(12):19310-19322. PubMed ID: 28038471
[TBL] [Abstract][Full Text] [Related]
10. CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG).
Balermpas P; Rödel F; Rödel C; Krause M; Linge A; Lohaus F; Baumann M; Tinhofer I; Budach V; Gkika E; Stuschke M; Avlar M; Grosu AL; Abdollahi A; Debus J; Bayer C; Stangl S; Belka C; Pigorsch S; Multhoff G; Combs SE; Mönnich D; Zips D; Fokas E
Int J Cancer; 2016 Jan; 138(1):171-81. PubMed ID: 26178914
[TBL] [Abstract][Full Text] [Related]
11. Rapid turnover of the CD8(+)CD28(-) T-cell subset of effector cells in the circulation of patients with head and neck cancer.
Tsukishiro T; Donnenberg AD; Whiteside TL
Cancer Immunol Immunother; 2003 Oct; 52(10):599-607. PubMed ID: 12827303
[TBL] [Abstract][Full Text] [Related]
12. Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer.
Junker N; Andersen MH; Wenandy L; Dombernowsky SL; Kiss K; Sørensen CH; Therkildsen MH; Von Buchwald C; Andersen E; Straten PT; Svane IM
Cytotherapy; 2011 Aug; 13(7):822-34. PubMed ID: 21428850
[TBL] [Abstract][Full Text] [Related]
13. PD1 blockade enhances K
Newton HS; Gawali VS; Chimote AA; Lehn MA; Palackdharry SM; Hinrichs BH; Jandarov R; Hildeman D; Janssen EM; Wise-Draper TM; Conforti L
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060146
[TBL] [Abstract][Full Text] [Related]
14. Expression of immune response biomarkers (PD‑L1, p16, CD3+ and CD8+ TILs) in recurrent head and neck squamous cell carcinoma within previously irradiated areas.
Pflumio C; Thomas J; Salleron J; Faivre JC; Borel C; Dolivet G; Sastre-Garau X; Geoffrois L
Oncol Rep; 2021 Mar; 45(3):1273-1283. PubMed ID: 33432367
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients.
Kim HR; Ha SJ; Hong MH; Heo SJ; Koh YW; Choi EC; Kim EK; Pyo KH; Jung I; Seo D; Choi J; Cho BC; Yoon SO
Sci Rep; 2016 Nov; 6():36956. PubMed ID: 27841362
[TBL] [Abstract][Full Text] [Related]
16. Oropharyngeal squamous cell carcinomas differentially express granzyme inhibitors.
van Kempen PM; Noorlag R; Swartz JE; Bovenschen N; Braunius WW; Vermeulen JF; Van Cann EM; Grolman W; Willems SM
Cancer Immunol Immunother; 2016 May; 65(5):575-85. PubMed ID: 26993499
[TBL] [Abstract][Full Text] [Related]
17. TILs in Head and Neck Cancer: Ready for Clinical Implementation and Why (Not)?
De Meulenaere A; Vermassen T; Aspeslagh S; Vandecasteele K; Rottey S; Ferdinande L
Head Neck Pathol; 2017 Sep; 11(3):354-363. PubMed ID: 28032290
[TBL] [Abstract][Full Text] [Related]
18. Immune-Checkpoint Blockade Opposes CD8
Pfannenstiel LW; Diaz-Montero CM; Tian YF; Scharpf J; Ko JS; Gastman BR
Cancer Immunol Res; 2019 Mar; 7(3):510-525. PubMed ID: 30728151
[TBL] [Abstract][Full Text] [Related]
19. Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma.
Nguyen N; Bellile E; Thomas D; McHugh J; Rozek L; Virani S; Peterson L; Carey TE; Walline H; Moyer J; Spector M; Perim D; Prince M; McLean S; Bradford CR; Taylor JM; Wolf GT;
Head Neck; 2016 Jul; 38(7):1074-84. PubMed ID: 26879675
[TBL] [Abstract][Full Text] [Related]
20. Prognostic markers in oropharyngeal squamous cell carcinoma: focus on CD70 and tumour infiltrating lymphocytes.
De Meulenaere A; Vermassen T; Aspeslagh S; Zwaenepoel K; Deron P; Duprez F; Rottey S; Ferdinande L
Pathology; 2017 Jun; 49(4):397-404. PubMed ID: 28427753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
